Last reviewed · How we verify
JS7 plasmid DNA and MVA62B vaccine — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
JS7 plasmid DNA and MVA62B vaccine (JS7 plasmid DNA and MVA62B vaccine) — GeoVax, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| JS7 plasmid DNA and MVA62B vaccine TARGET | JS7 plasmid DNA and MVA62B vaccine | GeoVax, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- JS7 plasmid DNA and MVA62B vaccine CI watch — RSS
- JS7 plasmid DNA and MVA62B vaccine CI watch — Atom
- JS7 plasmid DNA and MVA62B vaccine CI watch — JSON
- JS7 plasmid DNA and MVA62B vaccine alone — RSS
Cite this brief
Drug Landscape (2026). JS7 plasmid DNA and MVA62B vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/js7-plasmid-dna-and-mva62b-vaccine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab